Peter Rogan – President
Dr Rogan is an internationally recognized researcher in human genomics and bioinformatics who has authored more than 100 scientific publications and holds several related patents. As an inventor of SC technology, Dr. Rogan is president of Cytognomix. Dr. Rogan is a serial entrepreneur, having founded Phylogenetix Laboratories, a US company where preliminary development of SC technology occurred under a NIH SBIR grant. Dr. Rogan is currently Professor of Biochemistry at the Schulich School of Medicine and Dentistry, where he holds the Canada Research Chair in Genome Bioinformatics. He is committed to the success of Cytognomix by developing and commercializing new applications from our extensive intellectual property portfolio. Dr. Rogan received his PhD in Molecular Biophysics and Biochemistry from Yale, postdoctoral work at NCI, and holds degrees from the University of Grenoble and Johns Hopkins.
Joan Knoll – Chief Medical Officer
Dr. Knoll is direct Director of the Laboratory of Genomic Disorders, Schulich School of Medicine, at the University of Western Ontario is Professor in Pathology and is certified by the American Board of Medical Genetics in Cytogenetics and Molecular Genetics. She is also Medical Leader of Molecular Pathology at London Health Sciences Center, London Ontario. She has directed clinical cytogenetics laboratories at several academic research institutions and has authored more than 80 research publications. Dr. Knoll published an early detailed protocol on in situ hybridization (ISH) that remains widely cited, and continued to develop improvements in ISH, and co-invented SC-Probe technology with Dr. Rogan. Current projects are aimed at precisely defining chromosome abnormalities in chronic myelogenous leukemia and other diseases using SC FISH technology.
Glen Smeltzer – Interim Chief Financial Officer
Glen Smeltzer has over 21 years experience working with emerging technology, as a start-up CEO, partner in an early-stage venture capital fund, and a technology company incubator. Mr. Smeltzer also led Advantage Medical, a manufacturer of neurodiagnostic equipment, from start-up and market entry to ultimate profitability and eventual acquisition. Mr. Smeltzer, as part of the team at Fullarton Capital, managed venture investments in a variety of emerging Canadian technology companies. He currently serves as interim President of the Stiller Centre for Technology Commercialization in London, and as Director, Engineering and Natural Sciences, at WORLDiscoveries. Mr. Smeltzer holds a Chemical Engineering degree from the University of Waterloo, and an MBA from the Ivey School of Business at the University of Western Ontario.
